Disturbing the histone code in leukemia: translocations and mutations affecting histone methyl transferases

Area of Science:

• Molecular Biology
• Oncology
• Epigenetics

Background:

• Leukemia involves abnormal proliferation of early hematopoietic stem and progenitor cells.
• Genetic alterations, particularly in epigenetic modifiers, drive oncogenic transformation.
• Histone methyltransferases regulate gene expression through site-specific histone methylation.

Purpose of the Study:

• To review the role of histone methyltransferases in leukemia.
• To discuss the deregulation of specific histone methyltransferases (MLL1, DOT1L, EZH2, SETD2) in leukemia.
• To explore the therapeutic potential of histone methyltransferase inhibitors in leukemia treatment.

Main Methods:

• Review of scientific literature on histone methyltransferases and leukemia.
• Analysis of genetic alterations affecting histone methyltransferases in human leukemia.
• Evaluation of clinical studies on small molecule inhibitors of histone methyltransferases.

Main Results:

• Histone methyltransferases are frequently deregulated in leukemia via mutations, translocations, or complex alterations.
• Aberrant histone methylation patterns are reversed by targeted inhibitors.
• Small molecule inhibitors demonstrate potential to induce differentiation and apoptosis in leukemic cells.

Conclusions:

• Histone methyltransferases are critical epigenetic regulators implicated in leukemia pathogenesis.
• Targeting histone methyltransferases with small molecule inhibitors represents a promising therapeutic strategy for leukemia.
• Inhibitor-induced reversal of aberrant histone methylation offers a pathway to control leukemic blast proliferation.